ERBB2 and breast carcinoma: A 2022 paper discussesa clinical phase I study that evaluated the efficacy of [64Cu]-sarcophagine-bombesin (Figure 5) PET-CT as a diagnostic agent for restaging metastaticER+/PR+/HER2– breast cancer.